You are here

Article Text

Article menu

Download PDFPDF

Poster Presentation
Combining anti-CTLA4 with RG7787, an immunotoxin targeting mesothelin, promotes tumor eradication
  1. Jasmin Leshem1,
  2. Xiu-fen Liu1,
  3. Tapan Bera1,
  4. Masaki Terabe2,
  5. Jay A Berzofsky3,
  6. Birgit Bossenmaier4,
  7. Gerhard Niederfellner4 and
  8. Ira Pastan1
  1. Aff1 grid.48336.3a0000000419368075Laboratory of Molecular BiologyNational Cancer Institute Bethesda MD USA
  2. Aff2 grid.48336.3a0000000419368075National Cancer Institute Bethesda MD USA
  3. Aff3 grid.48336.3a0000000419368075NCI/CCR/Vaccine Branch Bethesda MD USA
  4. Aff4 grid.424277.0Roche Pharmaceutical Research &Early Development, Discovery OncologyInnovation Center Penzberg, Roche Diagnostics GmbH Penzberg Germany

https://doi.org/10.1186/2051-1426-3-S2-P190

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Meeting abstracts

    Introduction

    Antibodies to cytotoxic T-lymphocyte-associated protein 4 (CTLA4) potentiate an immune response against cancer. Response rates in melanoma patients are range from 10 to 19%[1]. To increase the efficacy and variety of cancer types treated by anti CTLA4, a combination therapy should be pursued. RG7787 is a recombinant immunotoxin composed of an anti-mesothelin Fab fused to a fragment of Pseudomonas exotoxin A (PE). RG7787 is currently tested in phase 1 trials for mesothelin expressing malignancies. We previously observed that an anti-mesothelin immunotoxin produced major tumor regressions in humans with advanced mesothelioma when combined with Cytoxan and Pentostatin apparently due to T cell activation[2] and we are exploring other ways to activate the immune system when cells are killed by immunotoxin. We hypothesize that combining RG7787 with anti CTLA4 will promote activation of the immune system and cancer elimination.

    Methods

    We transfected the 66C14 mouse breast cancer cell line with human mesothelin and grew the cancer cells in immune-competent BALB/c mice that express a human mesothelin transgene so that they will not reject the tumors. The transfected cells are killed by RG7787 in cell culture (IC50 12 ng/ml). Anti-tumor activity was evaluated by intra tumoral-injection of RG7787 combined with intra-peritoneal injection of anti CTLA4.

    Results

    We found that combining RG7787 with anti CTLA4 produced a 76% complete remission (CR) rate, while CR was reached in only 15% of the mice under anti CTLA4 monotherapy. The survival benefit was statistically significantly (P= 0.0012). No mice reached CR after treatment with RG7787 alone or in the PBS treated controls. Furthermore, re-challenging of the mice that reached CR with the parental cell line (66C14 without human mesothelin) resulted in complete rejection of the tumor in all the mice. We also found treatment with antibodies to CD8 decreased the CR rate to 12%, indicating that CD8+ T cells are necessary for the response.

    Conclusions

    Combining RG7787 with anti CTLA4 produces a high rate of complete remissions in a breast cancer model.

    References

    1. 1.↵
      1. Larkin J,
      2. Chiarion-Sileni V,
      3. Gonzalez R,
      4. Grob JJ,
      5. Cowey CL,
      6. Lao CD, et al
      . Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015;373:123–34. doi:10.1056/NEJMoa1504030
      OpenUrlCrossRefPubMed
    2. 2.↵
      1. Hassan R,
      2. Miller AC,
      3. Sharon E,
      4. Thomas A,
      5. Reynolds JC,
      6. Ling A, et al
      . Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression. Sci Transl Med. 2013;5:208208ra147doi:10.1126/scitranslmed.3006941
      OpenUrlAbstract/FREE Full Text